🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. PD-1 inhbitor+SHR0302

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. PEGENZILEUKIN, Isatuximab, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  3. PEGFILGRASTIM , Rinatabart Sesutecan

    Genmab A/S

    Locally advanced or metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  7. PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  8. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  9. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Australia Pty Ltd

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  10. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  12. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  13. PF-07850327 round

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  14. PI-88

    Biotech Pharmaceutical Co.,

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia and other blood cancers

    phase 2 small molecule active

    1 trial

  16. PLD and Carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. PM8002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. PRAVASTATIN

    The George Institute

    Patients with severe and radio-induced breast fibrosis after breast cancer

    phase 2 small molecule active

    1 trial

  19. PREDNISONE , ABIRATERONE , MDV3100

    Astellas Pharma GmbH

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  20. PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC

    Telix Innovations

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  21. Paclitaxel

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  22. Paclitaxel

    ONCOLYTICS BIOTECH INC

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. Paclitaxel

    ONCOLYTICS BIOTECH INC

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  24. Paclitaxel

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources